KalVista Pharmaceuticals, Inc. (KALV) had achieved a huge win announced just the other day on July 7th of 2025, whereby the FDA had approved its oral on-demand Hereditary Angioedema [HAE] plasma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback